Comprehensive diagnostics of acute myeloid leukemia by whole transcriptome RNA sequencing

Leukemia
Wibowo ArindrartoHendrik Veelken

Abstract

Acute myeloid leukemia (AML) is caused by genetic aberrations that also govern the prognosis of patients and guide risk-adapted and targeted therapy. Genetic aberrations in AML are structurally diverse and currently detected by different diagnostic assays. This study sought to establish whole transcriptome RNA sequencing as single, comprehensive, and flexible platform for AML diagnostics. We developed HAMLET (Human AML Expedited Transcriptomics) as bioinformatics pipeline for simultaneous detection of fusion genes, small variants, tandem duplications, and gene expression with all information assembled in an annotated, user-friendly output file. Whole transcriptome RNA sequencing was performed on 100 AML cases and HAMLET results were validated by reference assays and targeted resequencing. The data showed that HAMLET accurately detected all fusion genes and overexpression of EVI1 irrespective of 3q26 aberrations. In addition, small variants in 13 genes that are often mutated in AML were called with 99.2% sensitivity and 100% specificity, and tandem duplications in FLT3 and KMT2A were detected by a novel algorithm based on soft-clipped reads with 100% sensitivity and 97.1% specificity. In conclusion, HAMLET has the potential to p...Continue Reading

References

Oct 24, 2002·Blood·Sahar Barjesteh van Waalwijk van Doorn-KhosrovaniRuud Delwel
Dec 17, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Steffen KoschmiederDaniel G Tenen
Mar 24, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Stefan GröschelRuud Delwel
Feb 5, 2013·Blood·Marta PratcoronaUNKNOWN Grupo Cooperativo Para el Estudio y Tratamiento de las Leucemias Agudas Mieloblásticas
Mar 15, 2013·Genetic Testing and Molecular Biomarkers·Martin H van VlietErik H van Beers
May 3, 2013·The New England Journal of Medicine·UNKNOWN Cancer Genome Atlas Research NetworkGreg Eley
May 30, 2013·European Journal of Human Genetics : EJHG·Dorret I BoomsmaCornelia M van Duijn
Sep 11, 2014·The New England Journal of Medicine·Kathryn G RobertsCharles G Mullighan
Nov 27, 2014·The New England Journal of Medicine·Siddhartha JaiswalBenjamin L Ebert
Jan 22, 2015·Nucleic Acids Research·Matthew E RitchieGordon K Smyth
Sep 17, 2015·The New England Journal of Medicine·Hartmut DöhnerClara D Bloomfield
Oct 4, 2015·Nature·UNKNOWN 1000 Genomes Project ConsortiumGonçalo R Abecasis
Jun 9, 2016·The New England Journal of Medicine·Elli PapaemmanuilPeter J Campbell
Jun 28, 2016·Forensic Science International. Genetics·Kristiaan J van der GaagPeter de Knijff
Sep 13, 2016·Nature Genetics·Rik G H LindeboomBen Lehner
Feb 25, 2017·Frontiers in Pediatrics·Amanda C Winters, Kathrin M Bernt
Jun 22, 2017·The New England Journal of Medicine·Siddhartha JaiswalBenjamin L Ebert
Nov 9, 2017·The New England Journal of Medicine·B Taylor ThompsonKathleen D Liu
Nov 10, 2017·The New England Journal of Medicine·Chaker Ben Salem
Feb 6, 2018·Cell Stem Cell·Robert L BowmanRoss L Levine
Mar 6, 2018·Journal of the National Cancer Institute·Mei WangMattias Rantalainen
Oct 20, 2018·Nature·Jeffrey W TynerBrian J Druker
Jan 16, 2019·Nature Genetics·Zhaohui GuCharles G Mullighan

❮ Previous
Next ❯

Citations


❮ Previous
Next ❯

Datasets Mentioned

BETA
EGAC00001000956
EGAS00001003096
EGAD00001004187

Methods Mentioned

BETA
chromosomal aberrations
PCR
RNAseq
electrophoresis

Software Mentioned

FuMa
Ensembl
COSMIC
TMAP
Bcl2fastq
HAMLET
VarScan
ENSEMBL Variant Effect Predictor
Illumina
STAR

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukaemia & RNA

Acute myeloid leukaemia (AML) is a common hematological type of cancer. As the population ages, there has been a rise in the frequency of AML. RNA expression has been used to see if there are different genetic profiles that exist within AML and whether these may underpin the variations in survival rates. Here is the latest research on AML and RNA.

© 2021 Meta ULC. All rights reserved